Literature DB >> 2495195

SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats.

R Ilkiw1, L Todorovich-Hunter, K Maruyama, J Shin, M Rabinovitch.   

Abstract

In rats injected with the toxin monocrotaline, altered synthesis and distribution of pulmonary artery elastin suggest that increased elastase activity may be important in the development of vascular changes and progressive pulmonary hypertension. To test this hypothesis, male Sprague-Dawley rats (250-300 g) were given 40 mg/kg of the elastase inhibitor SC-39026 in a carboxymethylcellulose vehicle or vehicle only by gavage, 12 hours before and twice daily for 8 days after a single subcutaneous injection of either monocrotaline (60 mg/kg) or saline. Thirteen days after injection, indwelling cardiovascular catheters were inserted under pentobarbital anesthesia, and at 15 days after injection, pulmonary and systemic hemodynamic measurements were recorded with the animals awake. At post-mortem examination, the lungs were perfused and morphometric techniques applied for light and electron microscopic evaluation. Saline-injected rats given either SC-39026 or vehicle were similar in all features assessed. In contrast, monocrotaline-injected rats given SC-39026 had significantly lower mean pulmonary artery pressure than those given vehicle (21.0 +/- 1.6 vs. 27.5 +/- 0.8 mm Hg, p less than 0.05), and this correlated with a significant reduction in the number of abnormally muscularized arteries at alveolar wall level (r2 = 0.89, p less than 0.001). SC-39026 did not significantly reduce monocrotaline-induced medial hypertrophy of muscular arteries, endothelial injury, and associated subendothelial edema; nor was there a significant increase in the proportion of the medial elastin, although a trend was apparent. Additional groups of monocrotaline injected rats were followed 3 weeks after injection, but both SC-39026 and vehicle-treated rats were similar at this point. Our data suggest that increased serine elastase activity associated with endothelial injury may mediate early abnormal pulmonary vascular smooth muscle differentiation resulting in muscularization of normally nonmuscular peripheral arteries and pulmonary hypertension induced in rats by injection of the toxin monocrotaline. Lack of persistence of this protective effect suggests that there may be continued elastase activity in this model. Failure to inhibit medial hypertrophy with SC-39026 suggests that a different mechanism or a different elastase may be involved in this structural change.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495195     DOI: 10.1161/01.res.64.4.814

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  16 in total

1.  Simultaneous pulmonary and systemic blood pressure and ECG Interval measurement in conscious, freely moving rats.

Authors:  Markus Rey; Edgar W Weber; Patrick D Hess
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-03       Impact factor: 1.232

Review 2.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

3.  Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.

Authors:  Erquan Zhang; Junko Maruyama; Ayumu Yokochi; Yoshihide Mitani; Hirofumi Sawada; Masakatsu Nishikawa; Ning Ma; Kazuo Maruyama
Journal:  J Anesth       Date:  2015-05-01       Impact factor: 2.078

4.  Elafin in pulmonary arterial hypertension. Beyond targeting elastases.

Authors:  Hyung J Chun; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

5.  Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.

Authors:  Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-06-22       Impact factor: 5.464

Review 6.  Structure and composition of pulmonary arteries, capillaries, and veins.

Authors:  Mary I Townsley
Journal:  Compr Physiol       Date:  2012-01       Impact factor: 9.090

7.  Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis.

Authors:  S H Zaidi; C C Hui; A Y Cheah; X M You; M Husain; M Rabinovitch
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 8.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

Review 9.  World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.

Authors:  Kurt W Prins; Thenappan Thenappan
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

10.  The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin.

Authors:  L Zhu; D Wigle; A Hinek; J Kobayashi; C Ye; M Zuker; H Dodo; F W Keeley; M Rabinovitch
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.